Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study

被引:6
作者
Diamantopoulos, Panagiotis T. [1 ]
Stafylidis, Christos [1 ]
Vlachopoulou, Dimitra [1 ]
Kontandreopoulou, Christina-Nefeli [1 ]
Giannakopoulou, Nefeli [1 ]
Vardaka, Maria [2 ]
Mpouhla, Anthi [3 ]
Mastrogianni, Elpida [1 ]
Variami, Eleni [1 ]
Galanopoulos, Athanasios [2 ]
Pappa, Vasiliki [3 ]
Psichogiou, Mina [1 ]
Hatzakis, Angelos [4 ]
Viniou, Nora-Athina [1 ]
机构
[1] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Internal Med 1, Hematol Unit, Athens 11527, Greece
[2] G Gennimatas Dist Gen Hosp, Dept Clin Hematol, Athens, Greece
[3] Natl & Kapodistrian Univ Athens, Attikon Gen Hosp, Dept Internal Med 2, Haematol Div, Athens, Greece
[4] Natl & Kapodistrian Univ Athens, Med Sch, Dept Hyg Epidemiol & Med Stat, Athens, Greece
关键词
BNT162b2 mRNA Covid-19 vaccine; chronic lymphocytic leukemia; SARS-CoV-2; vaccine; venetoclax; HEMATOLOGIC MALIGNANCIES;
D O I
10.1177/20406207221090150
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Immunization of patients with chronic lymphocytic leukemia (CLL) with vaccines against several infectious diseases has proven insufficient. Data on seroconversion of patients with CLL after vaccination against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) are still young, but accumulating evidence shows low seroconversion rates. Methods: We conducted a prospective, noninterventional study evaluating the safety and immunogenicity of two doses of the BNT162b2 mRNA Covid-19 vaccine, administered 21 days apart in consecutive adult patients with CLL. Patients vaccinated with other vaccines against SARS-CoV-2, with a history of confirmed Coronavirus Disease 19 (COVID-19), with known human immunodeficiency virus infection, or with an inability to provide written informed consent were excluded. Sera were tested before the first and after the second dose of the vaccine for anti-SARS-CoV-2 receptor binding domain (RBD) spike protein IgG (anti-RBD), using the Abbott SARS-CoV-2 IgG II Quant assay (Abbott Laboratories, Abbott Park, IL, USA), with a cutoff value for seroconversion at 50 AU/ml. Results: Sixty-one patients (28 males/33 females) with CLL, with a median age of 61 years, were included in the study. The majority of the patients (82.0%) were lower (0-2) stage per the RAI staging system. The seroconversion rate at 14 days after the second dose was 45% and was correlated with RAI stage (0-2 versus 3-4; 51.0% versus 18.3%, p=0.047), the treatment status (treatment naive, previously treated, or actively treated patients; 63.0% versus 40.0% versus 26.1%, respectively, p =0.031), the number of previous treatment lines (0-2 versus >2; 55.3% versus 8.3%), p=0.004), and the platelet count of the patients (over or under 100 x 10(9)/L; 52.9% versus 10.0%, p= 0.015). Moreover, there was a positive linear relationship between the antibody titers and the gamma-globulin levels (r= 0.182, p= 0.046) and platelet count (r= 0.277, p= 0.002). Finally, patients actively treated with venetoclax had higher antibody titers than those treated with ibrutinib (15.8 AU/ml versus 0.0 AU/ml, p= 0.047). No safety issues were identified while the emergence of adverse events was not correlated with immunogenicity. Discussion: This study confirms results from previous studies on the low seroconversion rates in patients with CLL vaccinated with the BNT162b2 mRNA Covid-19 vaccine and on the detrimental effect of advanced disease and multiple treatment lines on seroconversion, while it is suggested that treatment with venetoclax may offer a chance for higher antibody titers, suggesting a treatment strategy change during the pandemic provided that this result is confirmed by larger studies specifically designed to address this issue.
引用
收藏
页数:12
相关论文
共 32 条
[1]   Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].
Baden, Lindsey R. ;
El Sahly, Hana M. ;
Essink, Brandon ;
Kotloff, Karen ;
Frey, Sharon ;
Novak, Rick ;
Diemert, David ;
Spector, Stephen A. ;
Rouphael, Nadine ;
Creech, C. Buddy ;
McGettigan, John ;
Khetan, Shishir ;
Segall, Nathan ;
Solis, Joel ;
Brosz, Adam ;
Fierro, Carlos ;
Schwartz, Howard ;
Neuzil, Kathleen ;
Corey, Larry ;
Gilbert, Peter ;
Janes, Holly ;
Follmann, Dean ;
Marovich, Mary ;
Mascola, John ;
Polakowski, Laura ;
Ledgerwood, Julie ;
Graham, Barney S. ;
Bennett, Hamilton ;
Pajon, Rolando ;
Knightly, Conor ;
Leav, Brett ;
Deng, Weiping ;
Zhou, Honghong ;
Han, Shu ;
Ivarsson, Melanie ;
Miller, Jacqueline ;
Zaks, Tal .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416
[2]   Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia [J].
Barmettler, Sara ;
Ong, Mei-Sing ;
Farmer, Jocelyn R. ;
Choi, Hyon ;
Walter, Jolan .
JAMA NETWORK OPEN, 2018, 1 (07)
[3]   Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients [J].
Benda, Magdalena ;
Mutschlechner, Beatrix ;
Ulmer, Hanno ;
Grabher, Claudia ;
Severgnini, Luciano ;
Volgger, Andreas ;
Reimann, Patrick ;
Lang, Theresia ;
Atzl, Michele ;
Huynh, Minh ;
Gasser, Klaus ;
Petrausch, Ulf ;
Fraunberger, Peter ;
Hartmann, Bernd ;
Winder, Thomas .
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (04) :523-531
[4]   Reduction in the rate and improvement in the prognosis of COVID-19 in haematological patients over time [J].
Cattaneo, Chiara ;
Pagani, Chiara ;
Cancelli, Valeria ;
Imberti, Luisa ;
Roccaro, Aldo M. ;
Notarangelo, Luigi D. ;
Rossi, Giuseppe .
LEUKEMIA, 2021, 35 (02) :632-634
[5]   SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study [J].
Colagrossi, Luna ;
Antonello, Maria ;
Renica, Silvia ;
Merli, Marco ;
Matarazzo, Elisa ;
Travi, Giovanna ;
Vecchi, Marta ;
Colombo, Jacopo ;
Muscatello, Antonio ;
Grasselli, Giacomo ;
Molteni, Silvia Nerini ;
Scaravilli, Vittorio ;
Cattaneo, Emanuele ;
Fanti, Diana ;
Vismara, Chiara ;
Bandera, Alessandra ;
Gori, Andrea ;
Puoti, Massimo ;
Cento, Valeria ;
Alteri, Claudia ;
Perno, Carlo Federico .
BMC INFECTIOUS DISEASES, 2021, 21 (01)
[6]   Prognostic factors in chronic lymphocytic leukemia-what do we need to know? [J].
Cramer, Paula ;
Hallek, Michael .
NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (01) :38-47
[7]   Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment [J].
de Weerdt, Iris ;
Hofland, Tom ;
de Boer, Renate ;
Dobber, Johan A. ;
Dubois, Julie ;
van Nieuwenhuize, Denise ;
Mobasher, Mehrdad ;
de Boer, Fransien ;
Hoogendoorn, Mels ;
Velders, Gerjo A. ;
van der Klift, Marjolein ;
Remmerswaal, Ester B. M. ;
Bemelman, Frederike J. ;
Niemann, Carsten U. ;
Kersting, Sabina ;
Levin, Mark-David ;
Eldering, Eric ;
Tonino, Sanne H. ;
Kater, Arnon P. .
BLOOD ADVANCES, 2019, 3 (17) :2642-2652
[8]   Chronic lymphocytic leukaemia [J].
Dighiero, G. ;
Hamblin, T. J. .
LANCET, 2008, 371 (9617) :1017-1029
[9]   Ibrutinib may impair serological responses to influenza vaccination [J].
Douglas, Abby P. ;
Trubiano, Jason A. ;
Barr, Ian ;
Leung, Vivian ;
Slavin, Monica A. ;
Tam, Constantine S. .
HAEMATOLOGICA, 2017, 102 (10) :E397-E399
[10]   Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia [J].
Hartkamp, A ;
Mulder, AHL ;
Rijkers, GT ;
van Velzen-Blad, H ;
Biesma, DH .
VACCINE, 2001, 19 (13-14) :1671-1677